Trial intelligence / Profile preview

Dasatinib in Primary Myelofibrosis

ChiCTR-IIh-16008649Phase 4Recruiting

Sponsor
The Peoples' Hospital of Jiaozuo City
Start
Jun 2014
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of dasatinib in primary myelofibrosis (PMF), sponsored by The Peoples' Hospital of Jiaozuo City. Primary endpoints: Spleen size and Complete blood count. Started Jun 2014; status: recruiting.

02

Drugs

dasatinib
03

Conditions

primary myelofibrosis (PMF)

Beyond the preview

Go deeper on ChiCTR-IIh-16008649.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-IIh-16008649.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call